[go: up one dir, main page]

GB202005340D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB202005340D0
GB202005340D0 GBGB2005340.1A GB202005340A GB202005340D0 GB 202005340 D0 GB202005340 D0 GB 202005340D0 GB 202005340 A GB202005340 A GB 202005340A GB 202005340 D0 GB202005340 D0 GB 202005340D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2005340.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Union Therapeutics AS
Original Assignee
Union Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Therapeutics AS filed Critical Union Therapeutics AS
Priority to GBGB2005340.1A priority Critical patent/GB202005340D0/en
Publication of GB202005340D0 publication Critical patent/GB202005340D0/en
Priority to US17/097,898 priority patent/US11045434B1/en
Priority to AU2021247378A priority patent/AU2021247378A1/en
Priority to JP2022560085A priority patent/JP2023520229A/en
Priority to US17/995,079 priority patent/US20230147683A1/en
Priority to IL296898A priority patent/IL296898A/en
Priority to US17/995,053 priority patent/US20230190685A1/en
Priority to CA3172166A priority patent/CA3172166A1/en
Priority to MX2022012359A priority patent/MX2022012359A/en
Priority to EP21715583.7A priority patent/EP4125805A1/en
Priority to EP21715582.9A priority patent/EP4125804A1/en
Priority to CN202180035793.9A priority patent/CN115701983A/en
Priority to PCT/EP2021/058046 priority patent/WO2021198115A1/en
Priority to AU2021248603A priority patent/AU2021248603A1/en
Priority to JP2022560369A priority patent/JP2023520542A/en
Priority to PCT/EP2021/058047 priority patent/WO2021198116A1/en
Priority to CN202180036954.6A priority patent/CN115701984A/en
Priority to KR1020227038248A priority patent/KR20230020952A/en
Priority to BR112022019519A priority patent/BR112022019519A2/en
Priority to BR112022019521A priority patent/BR112022019521A2/en
Priority to IL296909A priority patent/IL296909A/en
Priority to CA3173163A priority patent/CA3173163A1/en
Priority to KR1020227038253A priority patent/KR20230024883A/en
Priority to MX2022012360A priority patent/MX2022012360A/en
Priority to US17/330,067 priority patent/US11324708B1/en
Priority to US17/723,079 priority patent/US20220323384A1/en
Ceased legal-status Critical Current

Links

GBGB2005340.1A 2020-04-01 2020-04-09 Formulation Ceased GB202005340D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB2005340.1A GB202005340D0 (en) 2020-04-09 2020-04-09 Formulation
US17/097,898 US11045434B1 (en) 2020-04-01 2020-11-13 Niclosamide formulations for treating disease
MX2022012360A MX2022012360A (en) 2020-04-01 2021-03-26 Treatment.
PCT/EP2021/058046 WO2021198115A1 (en) 2020-04-01 2021-03-26 Treatment
PCT/EP2021/058047 WO2021198116A1 (en) 2020-04-01 2021-03-26 Formulation
US17/995,079 US20230147683A1 (en) 2020-04-01 2021-03-26 Treatment
IL296898A IL296898A (en) 2020-04-01 2021-03-26 care
US17/995,053 US20230190685A1 (en) 2020-04-01 2021-03-26 Formulation
CA3172166A CA3172166A1 (en) 2020-04-01 2021-03-26 Formulation
MX2022012359A MX2022012359A (en) 2020-04-01 2021-03-26 Formulation.
EP21715583.7A EP4125805A1 (en) 2020-04-01 2021-03-26 Formulation
EP21715582.9A EP4125804A1 (en) 2020-04-01 2021-03-26 Treatment
CN202180035793.9A CN115701983A (en) 2020-04-01 2021-03-26 Formulations
AU2021247378A AU2021247378A1 (en) 2020-04-01 2021-03-26 Formulation
AU2021248603A AU2021248603A1 (en) 2020-04-01 2021-03-26 Treatment
JP2022560369A JP2023520542A (en) 2020-04-01 2021-03-26 therapeutic drug
JP2022560085A JP2023520229A (en) 2020-04-01 2021-03-26 pharmaceutical formulation
CN202180036954.6A CN115701984A (en) 2020-04-01 2021-03-26 treat
KR1020227038248A KR20230020952A (en) 2020-04-01 2021-03-26 therapy
BR112022019519A BR112022019519A2 (en) 2020-04-01 2021-03-26 TREATMENT
BR112022019521A BR112022019521A2 (en) 2020-04-01 2021-03-26 FORMULATION
IL296909A IL296909A (en) 2020-04-01 2021-03-26 formulation
CA3173163A CA3173163A1 (en) 2020-04-01 2021-03-26 Treatment
KR1020227038253A KR20230024883A (en) 2020-04-01 2021-03-26 formulation
US17/330,067 US11324708B1 (en) 2020-04-01 2021-05-25 Niclosamide formulations for treating disease
US17/723,079 US20220323384A1 (en) 2020-04-01 2022-04-18 Niclosamide formulations for treating disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2005340.1A GB202005340D0 (en) 2020-04-09 2020-04-09 Formulation

Publications (1)

Publication Number Publication Date
GB202005340D0 true GB202005340D0 (en) 2020-05-27

Family

ID=70848140

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2005340.1A Ceased GB202005340D0 (en) 2020-04-01 2020-04-09 Formulation

Country Status (1)

Country Link
GB (1) GB202005340D0 (en)

Similar Documents

Publication Publication Date Title
GB202007546D0 (en) Formulation
IL319149A (en) Upadacitinib formulation
IL307849A (en) Sotorasib formulation
GB202102636D0 (en) Formulation
IL308046A (en) Alpelisib formulation
GB202108165D0 (en) Formulation
GB202107439D0 (en) Formulation
GB202107203D0 (en) Formulation
PL4138585T3 (en) Aerosolisable formulation
GB202103970D0 (en) Formulation
GB202102408D0 (en) Formulation
GB202016274D0 (en) Formulation
GB202010573D0 (en) Formulation
IL305977A (en) Formulation comprising ceralasertib
GB202005340D0 (en) Formulation
GB202003048D0 (en) Formulation
GB2599912B (en) New formulation
GB202115303D0 (en) New formulation
GB202108181D0 (en) New formulation
GB2595301B (en) Novel Formulation
GB2595453B (en) Novel Formulation
GB2595300B (en) Novel Formulation
IL324083A (en) Maropitant formulation
GB202318884D0 (en) Formulation
GB202316857D0 (en) Cannabinoid-based formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)